These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1398521)

  • 41. [Cancer of the prostate stage T1. Incidental carcinoma. Review of the literature and an appraisal of the classification].
    Leisinger HJ
    Ann Urol (Paris); 1994; 28(4):229-34. PubMed ID: 7979213
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes of phenotypic expression of prostatic antigen in secondary transitional cell carcinoma of the prostate: evidence for induction phenomenon as a mechanism for acquisition of prostatic antigens in prostatic transitional cell carcinoma.
    Mai KT; Yazdi HM; Farmer J
    Prostate; 2001 May; 47(3):172-82. PubMed ID: 11351346
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen.
    Moussa M; Kloth D; Peers G; Cherian MG; Frei JV; Chin JL
    Clin Invest Med; 1997 Dec; 20(6):371-80. PubMed ID: 9413634
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. I. Testing of a digitization system.
    Mohler JL; Partin AW; Lohr WD; Coffey DS
    J Urol; 1988 May; 139(5):1080-4. PubMed ID: 3361653
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The treatment of locally advanced (T3) prostatic carcinoma using radical prostatectomy or radiotherapy. A review].
    van den Ouden D; Schröder FH
    Tijdschr Gerontol Geriatr; 1998 Apr; 29(2):74-9. PubMed ID: 9615377
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Pseudohyperplastic carcinoma with xanthomatous changes: a neoplasm mimicking glandular hyperplasia of the prostate].
    Arista-Nasr J; Martínez-Benítez B; Fernández-Amador JA; Bornstein-Quevedo L; Albores-Saavedra J
    Actas Urol Esp; 2010 Apr; 34(4):333-9. PubMed ID: 20470695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma.
    Visakorpi T
    J Pathol; 1992 Sep; 168(1):7-13. PubMed ID: 1360498
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nucleolar and AgNOR-analysis of prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic carcinoma.
    Helpap B; Riede C
    Pathol Res Pract; 1995 Jun; 191(5):381-90. PubMed ID: 7479355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate.
    Ahlgren G; Lindholm K; Falkmer U; Abrahamsson PA
    Urology; 1997 Sep; 50(3):379-84. PubMed ID: 9301701
    [TBL] [Abstract][Full Text] [Related]  

  • 50. pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status.
    Abdou AG; Aiad HA; Sultan SM
    APMIS; 2008 Nov; 116(11):961-71. PubMed ID: 19132993
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists.
    Iczkowski KA; Egevad L; Ma J; Harding-Jackson N; Algaba F; Billis A; Camparo P; Cheng L; Clouston D; Comperat EM; Datta MW; Evans AG; Griffiths DF; Guo CC; Hailemariam S; Huang W; Humphrey PA; Jiang Z; Kahane H; Kristiansen G; La Rosa FG; Lopez-Beltran A; MacLennan GT; Magi-Galluzzi C; Merrimen J; Montironi R; Osunkoya AO; Picken MM; Rao N; Shah RB; Shanks JH; Shen SS; Tawfik OW; True LD; Van der Kwast T; Varma M; Wheeler TM; Zynger DL; Sahr N; Bostwick DG
    Ann Diagn Pathol; 2014 Dec; 18(6):333-42. PubMed ID: 25263387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
    BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Prostatic carcinoma: immunoperoxidase study with antisera against prostatic acid phosphatase and the prostate-specific antigen].
    Mathieu MC; Caillaud JM
    Bull Cancer; 1985; 72(5):405-13. PubMed ID: 2416371
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.
    van der Zee AG; Hollema H; Suurmeijer AJ; Krans M; Sluiter WJ; Willemse PH; Aalders JG; de Vries EG
    J Clin Oncol; 1995 Jan; 13(1):70-8. PubMed ID: 7799045
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Study of incidental carcinoma of the prostate. II. Nuclear DNA analysis].
    Fujita T; Akino H; Kanimoto Y; Okada K; Shiraishi T; Nakakuki K
    Hinyokika Kiyo; 1991 Sep; 37(9):1009-16. PubMed ID: 1785407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma.
    Fernandez-Pol JA; Fletcher JW; Hamilton PD; Klos DJ
    Anticancer Res; 1997; 17(3A):1519-30. PubMed ID: 9179190
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prediction of prognosis in untreated stage A2 prostatic carcinoma.
    Mohler JL; Partin AW; Epstein JI; Becker RL; Mikel UV; Sesterhenn IA; Mostofi FK; Gleason DF; Sharief Y; Coffey DS
    Cancer; 1992 Jan; 69(2):511-9. PubMed ID: 1728382
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer.
    Gallee MP; Visser-de Jong E; ten Kate FJ; Schroeder FH; Van der Kwast TH
    J Urol; 1989 Nov; 142(5):1342-6. PubMed ID: 2478729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.
    Sebo TJ; Cheville JC; Riehle DL; Lohse CM; Pankratz VS; Myers RP; Blute ML; Zincke H
    Cancer; 2001 Jun; 91(11):2196-204. PubMed ID: 11391602
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up.
    Thorson P; Vollmer RT; Arcangeli C; Keetch DW; Humphrey PA
    Mod Pathol; 1998 Jun; 11(6):543-51. PubMed ID: 9647592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.